Published in Gene Therapy Weekly, May 26th, 2005
This update was given at the 73rd annual meeting of the American Association of Neurological Surgeons (AANS) held in New Orleans, Louisiana.
Kaplitt highlighted the rationale for targeting the overactive subthalamic nucleus in Parkinson disease patients with the GAD (glutamic acid decarboxylase) gene, which synthesizes the major inhibitory neurotransmitter in the brain, gamma-aminobutyric acid...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.